However, in cervical cancer studies, miR‐944 plays an oncogenic role by targeting HWCW2 and S100PBP.12 A recent study showed that the expression level of miR‐944 in tumour tissues is less than that in adjacent non‐tumour tissues in CRC.13 Another study showed that the expression level of miR‐944 was frequently low in recurrent CRC patients.14 Dysregulation of GATA transcription factor 6 (GATA6) has been reported to affect the initiation and progression of tumours. Here, S100PBP is linked to neoplasm.